FGFR1 and lymphoid neoplasm: There is also an ongoing trial on the use of another FGFR inhibitor, pemigatinib (INCB054828) in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement (ClinicalTrials.gov identifier: NCT03011372).